The team at UAlberta spinoff company Metabolomic Technologies Inc. (from left): Richard Fedorak, Victor Tso, Haili Wang, Gigi Ho, Reg Joseph and Rae Foshaug.
Diagnostic test developed at UAlberta is more accurate, easier to use for detecting polyps in colon before they become cancerous. A colon cancer screening test developed at the University of Alberta is on its way to commercialization and potential worldwide use, through a new collaboration with a leading Chinese research institute and a U of A spinoff company. The groundbreaking research, led by U of A scientists Richard Fedorak and Haili Wang, has the potential to save lives through early and non-invasive diagnosis of precancerous polyps in the colon. The collaboration, supported by Alberta's Ministry of Enterprise and Advanced Education , enables the spinoff company Metabolomic Technologies Inc. (MTI) to begin validation trials in Canada and China for the promising new diagnostic test, known as PolypDx. BGI Shenzhen, a leading research institute in China, will run validation trials in that country and is partnering with MTI to develop the diagnostic tests for the Chinese market. The partnership demonstrates the U of A's global impact in discovering and advancing life-saving research, said Lorne Babiuk, vice-president of research.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
